Área de Medicina Clínica y Epidemiología Relapse and refractory multiple myeloma B-cell maturation antigen Chimeric antigen receptor T cell (CAR T-cell) therapy Immunotherapy
This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
Rodríguez-Otero, P. (Paula); Prósper-Cardoso, F. (Felipe Luis); Alfonso-Piérola, A. (Ana); et al. "CAR T-Cells in Multiple Myeloma Are Ready for Prime Time". Journal of Clinical Medicine. 9 (11), 2020, 3577
The survival of patients with multiple myeloma (MM) has been dramatically improved in the last decade thanks to the incorporation of second-generation proteasome inhibitors (PI), immunomodulatory drugs (IMID), and, more recently, anti-CD38 monoclonal antibodies (MoAb). Nevertheless, still, a major proportion of MM patients will relapse, underscoring the need for new therapies in this disease. Moreover, survival in patients failing the current standard of care regimens (including PI, IMIDs, and anti-CD38 MoAb), which is now defined as triple-class refractory, remains dismal, and new drugs with different mechanism of action are needed. B-cell maturation antigen (BCMA)-targeted therapies and in particular chimeric antigen receptor T cell (CAR T-cell) treatment have emerged as promising platforms to overcome refractoriness to conventional drugs. In this manuscript, we review the current available data regarding CAR T-cell therapy for MM, with a special focus on target selection, clinical results, limitations, and future strategies.